A 35-year-old woman presented to the emergency department (ED) with decreased level of consciousness. She had a threeday history of increasing headaches, vomiting, lethargy and disinterest towards her family. There was no other known medical history. Her vital signs were normal, and neurological examination demonstrated persistent myclonic jerks of the left frontalis and obicularis oris muscles. Initial laboratory investigations and a CT scan of the brain were unremarkable. Lumbar puncture showed mononuclear cells, 14x10 6 /L, polymorphonuclear cells, 6x10 6 /L; no bacteria; protein 0.45 g/L; glucose 4.7 mmol/L with a concurrent plasma level of 5.6 mmol/L. Herpes Simplex virus (HSV) polymerase chain reaction (PCR) was negative and enterococcus nucleic acid was not detected.
Routine EEG on day 2, on a non-intubated or sedated patient who was unresponsive to stimulus. There is no posterior background rhythm present and it contains generalised theta and delta waves. Occasional right frontal discharges were recorded (max F8) and there is no EEG correlate for episodes of facial twitching. The EEG provides support for a partial seizure disorder with evidence of an underlying encephalopathic process. There is no EEG evidence for status epilepticus. potassium channel antibodies.
Phenytoin, levetiracetam, midazolam and sodium valproate were used as anticonvulsants, along with propofol sedation. This regimen was increased over the next two days but there was continued seizure activity clinically and the EEG suggested refractory status epilepticus (see Figure 3 ). Subsequently, family history revealed a strong history of autoimmune disease, and on day six she was treated for auto-immune encephalitis with 1 g of methylprednisolone for three days, along with a five-day course of IV immunoglobulin therapy (0.4 g/kg/day). Repeat pelvic ultrasound and CT scan of the abdomen and pelvis on day eight demonstrated no cervical adenocarcinoma or ovarian teratoma.
On day nine, sodium thiopental therapy was commenced (a loading dose followed by an infusion) and using 24-hour EEG monitoring, burst suppression was achieved (see Figure 4 ). On day 11, voltage-gated potassium channel antibodies returned positive (142 pM, normal <85pM) despite initial testing being reported negative, and she was transferred to a quaternary centre for specialist epilepsy management. The sodium thiopental infusion was weaned and stopped on day 16 while oral prednisolone was continued. A further MRI brain scan on day 17 showed increased signalling in the bilateral parahippocampal gyrus confirming limbic encephalitis (Figure 5 ).
Figure 2
Coronal FLAIR on day 4. There is subtle T2/FLAIR hyperintensity involving both the hippocampal and parahippocampal regions symmetrically, demonstrated by both arrows. This is not associated with increased enhancement and may be secondary to seizure activity or it can represent non-specific encephalitis despite there being no enhancement.
Figure 3
Continuous EEG of our intubated and sedated patient in ICU on day 6. The EEG consisted of generalised high voltage continuous epileptiform discharges and these appeared to have a slight left-sided emphasis. The patient was clinically noted to have myoclonic left eye twitching and EMG of the orbicularis oculi muscle demonstrated an intermittent but inconsistent correlation between the twitch and a discharge at the vertex. 
Case reports
She received further immunosuppression with rituximab with an improvement in neurological symptoms. She was discharged from ICU on day 46, and transferred to a rehabilitation unit on day 116 on a pharmacological regimen of prednisone 25 mg daily, mycophenylate 1g bd, carbamazepine 600 mg bd, clonazepam 6 mg qid and levetiracetam 1g tds. She was subsequently discharged home on the same regimen.
Discussion Limbic encephalitis: classification, diagnosis and treatment
The limbic system of the brain controls functions such as memory, learning and emotions, and includes areas such as the hippocampus and amygdala. Limbic encephalitis (LE) presents subacutely with short-term memory deficits, headaches, confusion, agitation, sleep disturbances and seizures. 1, 2 Although limbic encephalitis is classically viewed as an autoimmune phenomenon, it can also be caused by infective organisms infiltrating the limbic system. Therefore the simplest categorisation is to divide LE into infective and autoimmune aetiologies, 3 and if an infective cause such as HSV is suspected then early intravenous anti-viral therapy is required. The autoimmune causes are further subdivided into paraneoplastic and non-paraneoplastic aetiologies, such as voltage-gated potassium channel antibody-related LE in this patient.
The association of neoplasia and LE was first described in 1960. 4 There are certain paraneoplastic antibodies that are associated with certain types of neoplasia: Anti-Hu and ANNA-3 with bronchial small cell carcinoma; Anti-Ma2 with testicular carcinoma; and CRMP5/CV2 with lymphoma. 5 Paraneoplastic automimmune LE may present months or even years before the detection of the neoplasia and this is reflected in the criteria commonly used to diagnose LE 6,7 ( Table 1) . The most recent criteria from 2005 by Graus and Siaz refer to the diagnosis of malignancy for up to five years after neurological symptoms presented.
Understanding of LE has increased significantly in recent years, and it is only in the last decade that it was recognised that autoimmune LE with no known or active malignancy represented a growing percentage of all LE diagnoses. Of these, voltage-gated potassium channel antibody-and NMDAreceptor antibody-related LE are the most commonly described. Voltage-gated potassium channels are a diverse group of membrane-bound proteins responsible for repolarising the nerve terminal after the passage of each action potential, and antibodies to them constitute 30% of all autoimmune encephalitis. 1, 8 One family of voltage-gated potassium channel antibodies are strongly expressed in the hippocampus, which was the area of involvement on the MRI of the patient we describe. They have recently been discovered in large numbers of patients with facio-brachial dystonic seizure disorder, which often precedes LE. 3 Our patient demonstrated significant facial myoclonus with an initially normal MRI scan and EEG, which would be consistent with this trend. Other antibodies apart from the NDMA receptor antibody which are associated with non-paraneoplastic autoimmune LE are AMPAR and GABABR.
Diagnosis of an autoimmune encephalitis and specifically LE is difficult. No causative agent is found in two-thirds of patients referred to specialist centres 9 and the initial differential diagnosis should be broad, including causes of subacute encephalopathy such as metabolic disorders, medications, toxins, nutritional deficiency such as Korsakoff syndrome, inflammatory, infiltrative, infective and degenerative disorders. Investigation requires a rigorous history (from family members if not possible from the patient), extensive laboratory investigations including blood and CSF sampling, and a low threshold for repeated neurological imaging. It has recently been demonstrated that the potassium channels may not be the antigenic target in LE. 10 The autoantibodies that were presumed to bind to the channel itself have been shown to act against certain proteins in the voltagegated potassium channel complex, which stain positive in diagnostic radioimmunoassay. Of these, the leucine-rich glioma inactivated-1 (LGI1), a protein secreted by the neurone, found mainly in the hippocampus as part of the voltage-gated potassium channel complex, may be the true auto-antigen in LE. 10, 11 It has been suggested that the disorder be re-classified LE associated with LGI1 antibodies, as almost all patients with LE have LGI1 antibodies and as, more importantly, LE is a problem with synaptic transmission that leads to encephalopathy, suggesting that it is a dysfunction of the synapse rather than the potassium channel. It has also been shown that features associated with anti-LGI1 LE include faciobrachial tonic seizures and, in up to 40% of patients, myoclonus, 2,10 as seen in the present case. The management of LE is based on its classification. Few cases have been shown to remit spontaneously and the majority require definitive treatment. 9 In suspected immunemediated LE, other differential diagnoses must be excluded prior to treatment. The detection of autoantibodies takes time, and a limited number of laboratories have the available assays. However treatment cannot be delayed, so neoplastic and paraneoplastic disease should be investigated first using tumour screening. 10 If positive, then resection or treatment of the primary neoplasia is the preferred treatment. Infection should also be investigated using serology and CSF-PCR. The treatment of paraneoplastic LE is not evidenced-based at this time and relies mainly on case reports. 11 If results from both neoplasia and infection investigations are negative then early immunosuppression should be commenced.
Immunosuppression has been shown to demonstrate disease responsiveness. Voltage-gated potassium channel antibodyrelated disease responds well to early IV methylprednisolone, IV immunoglobulin, and plasma exchange, which reduces antibody levels, and can lead to remission of symptoms. 12 Second-line therapy includes more aggressive immunosuppression with chemotherapeutic agents such as cyclophosphamide, mycophenylate and rituximab. 13 A recent case report demonstrated the use of rituximab in a patient with LE and B-cell chronic lymphocytic leukaemia. There was a substantial improvement in neurological symptoms and a decline in CSF CD3+ T cells, and the patient recovered completely. 14
Sodium thiopental and burst suppression via continuous EEG monitoring
Status epilepticus (SE) is defined as continuous seizures for more than 30 minutes, or two or more seizures occurring without return of full consciousness between episodes. Refractory status epilepticus (RSE) is defined as SE that does not respond to first-or second-line therapies. 18 It is more prevalent than recurrent SE, and is associated with a higher mortality and a failure to return to pre-morbid baseline regardless of agents used or achievement of burst suppression on EEG. 19 In this case, phenytoin and midazolam were used as first-line agents for RSE, with levetiracetam and sodium valproate added as second-line agents, with a propofol infusion for sedation administered in addition. Due to ongoing RSE, barbituate therapy with sodium thiopental was also instituted.
Burst suppression on EEG is a pattern of high amplitude bursts followed by low amplitude suppressions. In the cortices, bursts are synaptic depolarising potentials while suppression is the absence of cortical synaptic activity. As coma becomes deeper, the length of suppression increases and bursts decrease, leading to an isoelectric EEG 20 (see Figure 5 ). In RSE, the purpose of burst suppression on EEG is to stabilise seizure activity 12 to 24 hours prior to tapering drug infusions. However there is controversy about the duration of optimal burst suppression, with multiple studies unable to demonstrate whether different suppression intervals improve outcome. It has been suggested that greater suppression on EEG leads to fewer relapses and an overall better outcome; however some studies have shown that a more prolonged treatment time regardless of EEG stage is preferable. 21 Other case series have suggested that outcome is independent of the extent of burst suppression on EEG 16 which may explain why burst suppression is falling out of favour as an outcome goal in RSE.
Burst suppression is most usually attained using thiopental sodium, but because of concerns of increased ICU and hospital stay combined with the immunosuppressive effects of thiopental, it is falling out of favour. However thiopental has been shown to be more effective in RSE than propofol or midazolam 22 and it should still be considered as a valuable therapy. 19 After administering a loading dose, thiopental infusion at 3-5 mg/kg/hr can lead to burst suppression within 29 minutes, with termination of clinical and electrophysiological seizures. The dose of thiopental varies between patients, and resulting hypotension can require reduction in the infusion rate or the use of vasoactive medications. 23 Sodium thiopental decreases cerebral blood flow and metabolic oxygen demand in a dose-dependent way, by up to 50%. This reduction is similar to that achieved with propofol, however the reduction in mean arterial pressure is less and more predictable in comparison with propofol. 24 Due to its pharmacodynamic tolerance, non-linear elimination and rapid redistribution in tissues, sodium thiopental has a greater tendency to accumulate, and therefore length of sedation and seizure suppression is increased when compared to other second-line agents. It can cause hypokalaemia, which when treated with aggressive potassium replacement, can lead to hyperkalaemia on cessation of the infusion. 25 Continuous EEG monitoring provides dynamic information about neurological electrophysiological status and allows early detection of changes. This is beneficial as there is often limited scope for a full neurological examination. Its role in diagnosis and management of non-convulsive status epilepticus (NSCE) is established, but its place in the management of RSE is controversial. Some studies suggest that it aids in medical therapy and sedation guidance only in patients with NCSE after a convulsive episode, while other studies suggest its use in both RSE and NCSE. 26 There are suggestions that detection and treatment of the convulsive status can lead to decreased morbidity and mortality. 27 A normal pattern on EEG usually is associated with good outcomes, while burst suppression despite no significant use of anti-epileptic drugs or sedative infusions leads to increased mortality in those with seizures. Continuous EEG monitoring is also used in ICP management of traumatic brain injury, early identification of cerebral ischemia and subarachnoid haemorrhage-related vasospasm.
There are difficulties associated with using continuous EEG monitoring in the ICU. The equipment itself can be affected by the environment: connections to the patient can vary recordings and artefacts from movement or electrical devices can cloud recordings. 28 The information gathered requires expert review and interpretation, which may not be immediately available in the ICU. Real-time analysis as changes occur, can require both on-site and remote analysis capabilities, and despite increased training of ICU staff to recognise EEG patterns, this level of expertise may not be adequate. It has been shown that multichannel EEG plus continuous EEG has advantages over either modality alone for monitoring burst suppression, especially in paediatric patients. 29 Our patient benefited from continuous EEG monitoring, as we were able to titrate sodium thiopental dose to burst suppression. This facilitated intermittent boluses and increases in the underlying infusion rate to achieve burst suppression, and also allowed the consulting neurologist to track any evolution of the seizure pattern by retrospective analysis of the previous 24 hours of recordings. The level of EEG knowledge required to achieve this ability should not be beyond the bounds of any intensivist. The evidence for continuous EEG monitoring is becoming stronger, and the counter-arguments such as cost, data collection, storage and qualified interpretation are beginning to 'hold less water.'
Summary
Limbic encephalitis is a rare condition with potentially severe sequelae. It remains difficult to diagnose and therefore it requires a high index of suspicion and needs to be entertained early in the differential diagnosis to allow appropriate investigation and management. Voltage-gated potassium channel LE is a subtype which may or may not be associated with an underlying malignancy, and a positive antibody result necessitates a search for the malignancy. Refractory SE is a complication of LE and requires an aggressive anti-epileptic regimen. However, some of the newer agents may not be as successful as the tried and tested regimen of sodium thiopental. The use of continuous EEG monitoring in the ICU is controversial; however, many of the arguments that have been previously used to preclude its use are now being superseded.
